Symbols / MDWD Stock $16.72 +0.42% MediWound Ltd.
MDWD (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Ratings
Current target
$16.72
Low
$25.00
High
$39.00
Mean
$31.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-21 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-05-22 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-28 | init | Craig-Hallum | — → Buy | $39 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-11-27 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-07-16 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-01-16 | main | HC Wainwright & Co. | Buy → Buy | $28 |
| 2023-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2023-09-21 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2023-08-17 | main | Oppenheimer | Outperform → Outperform | $36 |
| 2023-08-17 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2023-05-31 | reit | Oppenheimer | Outperform → Outperform | $63 |
| 2023-05-31 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $23 |
| 2023-01-04 | main | HC Wainwright & Co. | — → Buy | $23 |
- Is MediWound (MDWD) stock forming a trend channel (Technical Weakness) 2026-04-20 - Income Investing - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 16
- Why (MDWD) Price Action Is Critical for Tactical Trading - Stock Traders Daily Wed, 22 Apr 2026 09
- U.S. wound experts favor less invasive care, aligning with MediWound - Stock Titan Mon, 13 Apr 2026 07
- MediWound Is A Buy Opportunity On The Dip (NASDAQ:MDWD) - Seeking Alpha ue, 02 Sep 2025 07
- MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 05 Mar 2026 08
- MediWound Highlights Vericel’s $197 Million BARDA Contract for NexoBrid - TipRanks hu, 02 Apr 2026 07
- Understanding Momentum Shifts in (MDWD) - Stock Traders Daily Sat, 11 Apr 2026 08
- MediWound boosts burn drug output sixfold, guides to $24–26M 2026 sales - Stock Titan hu, 05 Mar 2026 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 02 Apr 2024 18
- U.S. stockpile plans include NexoBrid under BARDA deal worth up to $197M - Stock Titan hu, 02 Apr 2026 07
- From burns to ulcers: new MediWound EscharEx data heads to 3 meetings - Stock Titan ue, 07 Apr 2026 07
- BARDA’s up-to-$197M NexoBrid contract highlighted by MediWound (MDWD) - Stock Titan hu, 02 Apr 2026 07
- MediWound's 2025 SEC annual report now online, free print by request - Stock Titan hu, 05 Mar 2026 08
- MediWound (MDWD) director details options, RSU and share holdings - Stock Titan Wed, 25 Mar 2026 07
- MediWound (MDWD) EVP Meyer Yaron files Form 3 on equity holdings - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
16.96
-16.14%
|
20.22
+8.22%
|
18.69
-29.48%
|
26.50
|
| Operating Revenue |
|
16.96
-16.14%
|
20.22
+8.22%
|
18.69
-29.48%
|
26.50
|
| Cost Of Revenue |
|
13.71
-22.08%
|
17.59
+16.42%
|
15.11
+13.33%
|
13.33
|
| Reconciled Cost Of Revenue |
|
12.13
-25.71%
|
16.33
+16.33%
|
14.04
+13.84%
|
12.33
|
| Gross Profit |
|
3.25
+23.54%
|
2.63
-26.38%
|
3.58
-72.82%
|
13.16
|
| Operating Expense |
|
28.53
+29.60%
|
22.02
+15.39%
|
19.08
-8.39%
|
20.83
|
| Research And Development |
|
14.32
+61.30%
|
8.88
+18.90%
|
7.47
-26.66%
|
10.18
|
| Selling General And Administration |
|
13.93
+7.86%
|
12.91
+13.47%
|
11.38
+9.70%
|
10.37
|
| Selling And Marketing Expense |
|
3.87
+21.06%
|
3.20
+14.02%
|
2.80
+37.47%
|
2.04
|
| General And Administrative Expense |
|
10.06
+3.52%
|
9.71
+13.30%
|
8.57
+2.90%
|
8.33
|
| Salaries And Wages |
|
6.92
+5.44%
|
6.57
+19.14%
|
5.51
+10.66%
|
4.98
|
| Other Gand A |
|
3.13
-0.48%
|
3.15
+2.78%
|
3.06
-8.62%
|
3.35
|
| Other Operating Expenses |
|
—
|
—
|
—
|
0.68
|
| Total Expenses |
|
42.24
+6.65%
|
39.60
+15.85%
|
34.19
+0.09%
|
34.16
|
| Operating Income |
|
-25.28
-30.43%
|
-19.38
-25.04%
|
-15.50
-102.34%
|
-7.66
|
| Total Operating Income As Reported |
|
-25.27
-30.24%
|
-19.40
-26.88%
|
-15.29
-83.22%
|
-8.35
|
| EBITDA |
|
-21.47
+23.12%
|
-27.93
-481.71%
|
-4.80
+73.69%
|
-18.25
|
| Normalized EBITDA |
|
-22.21
-29.13%
|
-17.20
-35.78%
|
-12.67
-35.76%
|
-9.33
|
| Reconciled Depreciation |
|
1.86
+25.42%
|
1.48
+13.81%
|
1.30
+2.44%
|
1.27
|
| EBIT |
|
-23.33
+20.68%
|
-29.41
-381.83%
|
-6.10
+68.73%
|
-19.52
|
| Total Unusual Items |
|
0.74
+106.90%
|
-10.73
-236.37%
|
7.87
+188.21%
|
-8.92
|
| Total Unusual Items Excluding Goodwill |
|
0.74
+106.90%
|
-10.73
-236.37%
|
7.87
+188.21%
|
-8.92
|
| Special Income Charges |
|
—
|
—
|
0.21
|
—
|
| Other Special Charges |
|
—
|
—
|
-0.21
|
—
|
| Net Income |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Pretax Income |
|
-23.71
+21.39%
|
-30.16
-361.84%
|
-6.53
+66.54%
|
-19.52
|
| Net Non Operating Interest Income Expense |
|
0.82
+2431.43%
|
-0.04
-103.17%
|
1.10
+148.85%
|
-2.26
|
| Interest Expense Non Operating |
|
0.38
-49.47%
|
0.75
+76.11%
|
0.43
|
0.00
|
| Net Interest Income |
|
0.82
+2431.43%
|
-0.04
-103.17%
|
1.10
+148.85%
|
-2.26
|
| Interest Expense |
|
0.38
-49.47%
|
0.75
+76.11%
|
0.43
|
0.00
|
| Interest Income Non Operating |
|
1.86
-9.23%
|
2.05
-12.52%
|
2.34
+767.04%
|
0.27
|
| Interest Income |
|
1.86
-9.23%
|
2.05
-12.52%
|
2.34
+767.04%
|
0.27
|
| Other Income Expense |
|
0.75
+107.01%
|
-10.75
-236.60%
|
7.87
+181.93%
|
-9.60
|
| Other Non Operating Income Expenses |
|
0.01
+172.22%
|
-0.02
|
—
|
-0.68
|
| Gain On Sale Of Security |
|
0.74
+106.90%
|
-10.73
-240.13%
|
7.66
+185.85%
|
-8.92
|
| Tax Provision |
|
0.17
+177.05%
|
0.06
-67.03%
|
0.18
+137.18%
|
0.08
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.16
+106.90%
|
-2.25
-236.37%
|
1.65
+188.21%
|
-1.87
|
| Net Income Including Noncontrolling Interests |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Net Income From Continuing And Discontinued Operation |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Net Income Continuous Operations |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-24.46
-12.48%
|
-21.75
-68.19%
|
-12.93
-3.00%
|
-12.55
|
| Net Income Common Stockholders |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Diluted EPS |
|
-2.10
+30.69%
|
-3.03
-304.00%
|
-0.75
+80.92%
|
-3.93
|
| Basic EPS |
|
-2.10
+30.69%
|
-3.03
-304.00%
|
-0.75
+80.92%
|
-3.93
|
| Basic Average Shares |
|
11.38
+14.23%
|
9.96
+10.50%
|
9.01
+80.73%
|
4.99
|
| Diluted Average Shares |
|
11.38
+14.23%
|
9.96
+10.50%
|
9.01
+80.73%
|
4.99
|
| Diluted NI Availto Com Stockholders |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Depreciation Amortization Depletion Income Statement |
|
0.29
+26.32%
|
0.23
-2.98%
|
0.23
-14.23%
|
0.27
|
| Depreciation And Amortization In Income Statement |
|
0.29
+26.32%
|
0.23
-2.98%
|
0.23
-14.23%
|
0.27
|
| Total Other Finance Cost |
|
0.66
-50.19%
|
1.33
+64.12%
|
0.81
-67.92%
|
2.53
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
86.25
+17.36%
|
73.50
+10.59%
|
66.46
+32.88%
|
50.02
|
| Current Assets |
|
59.96
+14.96%
|
52.16
+4.97%
|
49.70
+8.41%
|
45.84
|
| Cash Cash Equivalents And Short Term Investments |
|
53.14
+23.12%
|
43.16
+263.74%
|
11.87
-64.99%
|
33.90
|
| Cash And Cash Equivalents |
|
4.80
-47.58%
|
9.15
-22.85%
|
11.87
-64.99%
|
33.90
|
| Cash Financial |
|
4.80
-47.58%
|
9.15
-22.85%
|
11.87
-64.99%
|
33.90
|
| Other Short Term Investments |
|
48.34
+42.15%
|
34.01
+14.59%
|
29.68
|
0.00
|
| Receivables |
|
2.37
-59.47%
|
5.85
+32.43%
|
4.42
-54.42%
|
9.70
|
| Accounts Receivable |
|
1.62
-66.23%
|
4.80
+29.73%
|
3.70
-60.35%
|
9.33
|
| Gross Accounts Receivable |
|
1.73
-64.75%
|
4.92
+32.68%
|
3.71
-60.30%
|
9.33
|
| Allowance For Doubtful Accounts Receivable |
|
-0.11
+4.27%
|
-0.12
-1850.00%
|
-0.01
-200.00%
|
-0.00
|
| Other Receivables |
|
0.75
-28.61%
|
1.05
+46.31%
|
0.72
+98.07%
|
0.36
|
| Inventory |
|
4.09
+52.04%
|
2.69
-5.41%
|
2.85
+44.98%
|
1.96
|
| Raw Materials |
|
1.72
+19.25%
|
1.44
+45.13%
|
0.99
+8.98%
|
0.91
|
| Finished Goods |
|
2.37
+89.98%
|
1.25
-32.58%
|
1.85
+76.29%
|
1.05
|
| Prepaid Assets |
|
0.36
-21.62%
|
0.46
-36.57%
|
0.72
+151.57%
|
0.29
|
| Restricted Cash |
|
—
|
34.01
+13.95%
|
29.84
|
0.00
|
| Total Non Current Assets |
|
26.29
+23.24%
|
21.33
+27.25%
|
16.76
+301.44%
|
4.18
|
| Net PPE |
|
25.79
+24.03%
|
20.80
+30.57%
|
15.93
+344.74%
|
3.58
|
| Gross PPE |
|
35.21
+22.56%
|
28.73
+24.56%
|
23.06
+129.61%
|
10.04
|
| Accumulated Depreciation |
|
-9.41
-18.73%
|
-7.93
-11.13%
|
-7.14
-10.41%
|
-6.46
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
8.07
+13.34%
|
7.12
|
—
|
—
|
| Machinery Furniture Equipment |
|
23.16
+27.61%
|
18.15
+39.75%
|
12.99
+134.04%
|
5.55
|
| Other Properties |
|
—
|
—
|
6.70
+451.28%
|
1.22
|
| Leases |
|
3.97
+15.04%
|
3.45
+2.25%
|
3.38
+2.93%
|
3.28
|
| Goodwill And Other Intangible Assets |
|
0.03
-66.67%
|
0.10
-40.00%
|
0.17
-28.57%
|
0.23
|
| Other Intangible Assets |
|
0.03
-66.67%
|
0.10
-40.00%
|
0.17
-28.57%
|
0.23
|
| Non Current Accounts Receivable |
|
0.03
|
—
|
0.23
+29.44%
|
0.18
|
| Other Non Current Assets |
|
0.44
+0.00%
|
0.44
-0.23%
|
0.44
+139.13%
|
0.18
|
| Total Liabilities Net Minority Interest |
|
42.62
+0.66%
|
42.34
+21.45%
|
34.86
-10.84%
|
39.10
|
| Current Liabilities |
|
25.71
-3.14%
|
26.54
+46.43%
|
18.12
+50.33%
|
12.06
|
| Payables And Accrued Expenses |
|
11.00
+31.24%
|
8.38
-10.80%
|
9.39
-3.66%
|
9.75
|
| Payables |
|
3.91
-11.23%
|
4.41
-26.30%
|
5.98
-17.85%
|
7.28
|
| Accounts Payable |
|
3.61
-11.94%
|
4.10
-3.01%
|
4.22
-25.34%
|
5.66
|
| Other Payable |
|
0.22
-2.65%
|
0.23
-86.51%
|
1.68
+27.09%
|
1.32
|
| Current Accrued Expenses |
|
7.08
+78.37%
|
3.97
+16.34%
|
3.41
+38.16%
|
2.47
|
| Employee Benefits |
|
0.47
+16.83%
|
0.40
-11.40%
|
0.46
+26.67%
|
0.36
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
0.42
|
| Current Deferred Liabilities |
|
1.18
+158.42%
|
0.46
+1804.17%
|
0.02
-61.90%
|
0.06
|
| Current Deferred Revenue |
|
1.18
+158.42%
|
0.46
+1804.17%
|
0.02
-61.90%
|
0.06
|
| Other Current Liabilities |
|
13.53
-23.58%
|
17.70
+103.35%
|
8.71
+288.31%
|
2.24
|
| Total Non Current Liabilities Net Minority Interest |
|
16.91
+7.04%
|
15.80
-5.60%
|
16.74
-38.11%
|
27.05
|
| Long Term Debt And Capital Lease Obligation |
|
8.15
+25.17%
|
6.51
+2.57%
|
6.35
+650.59%
|
0.85
|
| Long Term Capital Lease Obligation |
|
8.15
+25.17%
|
6.51
+2.57%
|
6.35
+650.59%
|
0.85
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.47
+16.83%
|
0.40
-11.40%
|
0.46
+26.67%
|
0.36
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
0.74
|
0.00
|
0.00
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
0.74
|
0.00
|
0.00
|
| Other Non Current Liabilities |
|
8.29
+1.74%
|
8.15
-17.96%
|
9.93
-2.93%
|
10.23
|
| Stockholders Equity |
|
43.63
+40.06%
|
31.15
-1.40%
|
31.59
+189.49%
|
10.91
|
| Common Stock Equity |
|
43.63
+40.06%
|
31.15
-1.40%
|
31.59
+189.49%
|
10.91
|
| Capital Stock |
|
0.26
+20.00%
|
0.21
+16.85%
|
0.18
+28.67%
|
0.14
|
| Common Stock |
|
0.26
+20.00%
|
0.21
+16.85%
|
0.18
+28.67%
|
0.14
|
| Share Issued |
|
12.84
+18.92%
|
10.79
+17.04%
|
9.22
+27.37%
|
7.24
|
| Ordinary Shares Number |
|
12.84
+18.92%
|
10.79
+17.04%
|
9.22
+27.37%
|
7.24
|
| Additional Paid In Capital |
|
272.33
+15.40%
|
236.00
+14.42%
|
206.25
+15.30%
|
178.88
|
| Retained Earnings |
|
-228.93
-11.65%
|
-205.05
-17.29%
|
-174.82
-4.00%
|
-168.11
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.03
-190.91%
|
-0.01
+38.89%
|
-0.02
-260.00%
|
-0.01
|
| Total Equity Gross Minority Interest |
|
43.63
+40.06%
|
31.15
-1.40%
|
31.59
+189.49%
|
10.91
|
| Total Capitalization |
|
43.63
+40.06%
|
31.15
-1.40%
|
31.59
+189.49%
|
10.91
|
| Working Capital |
|
34.26
+33.70%
|
25.62
-18.84%
|
31.57
-6.55%
|
33.78
|
| Invested Capital |
|
43.63
+40.06%
|
31.15
-1.40%
|
31.59
+189.49%
|
10.91
|
| Total Debt |
|
8.15
+25.17%
|
6.51
+2.57%
|
6.35
+650.59%
|
0.85
|
| Capital Lease Obligations |
|
8.15
+25.17%
|
6.51
+2.57%
|
6.35
+650.59%
|
0.85
|
| Net Tangible Assets |
|
43.60
+40.40%
|
31.05
-1.20%
|
31.43
+194.21%
|
10.68
|
| Tangible Book Value |
|
43.60
+40.40%
|
31.05
-1.20%
|
31.43
+194.21%
|
10.68
|
| Derivative Product Liabilities |
|
—
|
—
|
7.30
-53.25%
|
15.61
|
| Dueto Related Parties Current |
|
0.09
+0.00%
|
0.09
+3.61%
|
0.08
-72.96%
|
0.31
|
| Foreign Currency Translation Adjustments |
|
-0.03
-190.91%
|
-0.01
+38.89%
|
-0.02
-260.00%
|
-0.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.12
-18.33%
|
-13.62
-30.19%
|
-10.46
+11.95%
|
-11.88
|
| Cash Flow From Continuing Operating Activities |
|
-16.12
-18.33%
|
-13.62
-30.19%
|
-10.46
+11.95%
|
-11.88
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
—
|
0.00
|
| Net Income From Continuing Operations |
|
-23.88
+20.99%
|
-30.22
-350.03%
|
-6.72
+65.73%
|
-19.60
|
| Depreciation Amortization Depletion |
|
1.86
+25.42%
|
1.48
+13.81%
|
1.30
+2.44%
|
1.27
|
| Depreciation And Amortization |
|
1.86
+25.42%
|
1.48
+13.81%
|
1.30
+2.44%
|
1.27
|
| Other Non Cash Items |
|
0.20
+1775.00%
|
-0.01
+99.07%
|
-1.29
-691.74%
|
0.22
|
| Pension And Employee Benefit Expense |
|
0.03
+203.33%
|
-0.03
-136.14%
|
0.08
-23.85%
|
0.11
|
| Stock Based Compensation |
|
3.11
-0.96%
|
3.14
+61.75%
|
1.94
-0.31%
|
1.95
|
| Operating Gains Losses |
|
-2.18
-120.32%
|
10.72
+233.38%
|
-8.04
-169.76%
|
11.52
|
| Gain Loss On Investment Securities |
|
-2.16
-120.16%
|
10.70
+228.81%
|
-8.31
-176.32%
|
10.89
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.05
-208.51%
|
0.05
-75.13%
|
0.19
-64.00%
|
0.53
|
| Change In Working Capital |
|
4.77
+275.35%
|
1.27
-45.63%
|
2.34
+132.25%
|
-7.24
|
| Change In Receivables |
|
4.88
+577.57%
|
-1.02
-121.43%
|
4.76
+166.00%
|
-7.22
|
| Changes In Account Receivables |
|
3.21
+381.42%
|
-1.14
-120.17%
|
5.66
+174.62%
|
-7.58
|
| Change In Inventory |
|
-1.36
-828.88%
|
0.19
+120.64%
|
-0.91
-25.66%
|
-0.72
|
| Change In Payables And Accrued Expense |
|
1.25
+35.86%
|
0.92
+160.64%
|
-1.52
-318.99%
|
0.69
|
| Change In Payable |
|
1.25
+35.86%
|
0.92
+160.64%
|
-1.52
-318.99%
|
0.69
|
| Change In Account Payable |
|
2.35
+478.82%
|
0.41
+168.35%
|
-0.59
-243.48%
|
0.41
|
| Change In Other Working Capital |
|
—
|
1.18
|
—
|
—
|
| Investing Cash Flow |
|
-17.95
-113.77%
|
-8.40
+75.53%
|
-34.32
-7035.34%
|
-0.48
|
| Cash Flow From Continuing Investing Activities |
|
-17.95
-113.77%
|
-8.40
+75.53%
|
-34.32
-7035.34%
|
-0.48
|
| Cash From Discontinued Investing Activities |
|
—
|
—
|
—
|
—
|
| Net PPE Purchase And Sale |
|
-5.50
+12.24%
|
-6.27
+2.95%
|
-6.46
-1064.68%
|
-0.56
|
| Purchase Of PPE |
|
-5.50
+12.24%
|
-6.27
+2.95%
|
-6.46
-1064.68%
|
-0.56
|
| Capital Expenditure |
|
-5.50
+12.24%
|
-6.27
+2.95%
|
-6.46
-1064.68%
|
-0.56
|
| Net Investment Purchase And Sale |
|
-14.04
-220.75%
|
-4.38
+85.32%
|
-29.80
|
0.00
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
29.62
+52.73%
|
19.39
-15.37%
|
22.92
-35.92%
|
35.76
|
| Cash Flow From Continuing Financing Activities |
|
29.62
+52.73%
|
19.39
-15.37%
|
22.92
-35.92%
|
35.76
|
| Net Common Stock Issuance |
|
27.42
+23.69%
|
22.16
-11.02%
|
24.91
-35.10%
|
38.38
|
| Proceeds From Stock Option Exercised |
|
3.63
+200.00%
|
1.21
|
0.00
-100.00%
|
0.01
|
| Net Other Financing Charges |
|
-1.43
+64.18%
|
-3.98
-99.85%
|
-1.99
+24.14%
|
-2.63
|
| Changes In Cash |
|
-4.45
-69.43%
|
-2.63
+87.99%
|
-21.87
-193.47%
|
23.40
|
| Effect Of Exchange Rate Changes |
|
0.10
+213.10%
|
-0.08
+47.50%
|
-0.16
+70.86%
|
-0.55
|
| Beginning Cash Position |
|
9.15
-22.85%
|
11.87
-64.99%
|
33.90
+206.85%
|
11.05
|
| End Cash Position |
|
4.80
-47.58%
|
9.15
-22.85%
|
11.87
-64.99%
|
33.90
|
| Free Cash Flow |
|
-21.63
-8.69%
|
-19.90
-17.53%
|
-16.93
-36.09%
|
-12.44
|
| Common Stock Issuance |
|
27.42
+23.69%
|
22.16
-11.02%
|
24.91
-35.10%
|
38.38
|
| Interest Received CFI |
|
1.59
-29.35%
|
2.25
+15.67%
|
1.95
+2531.08%
|
0.07
|
| Issuance Of Capital Stock |
|
27.42
+23.69%
|
22.16
-11.02%
|
24.91
-35.10%
|
38.38
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|